Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a San Francisco-based commercial stage biotechnology company, announced on Thursday that VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), oestrogen receptor 1 (ESR1)-mutated advanced, or metastatic breast cancer (mBC), as detected by a US Food and Drug Administration (FDA)-authorised test, with disease progression following at least one line of endocrine therapy.

According to Rigel Pharmaceuticals, VEPPANU is the first and only FDA-approved PROteolysis TArgeting Chimera (PROTAC). PROTACs are a new class of heterobifunctional protein degraders designed to harness the body's natural machinery to selectively degrade, rather than inhibit, disease-causing proteins. The recommended dosage of VEPPANU is 200 mg taken orally once daily. VEPPANU is immediately available through Rigel's network of specialty distributors and specialty pharmacies in the United States and Puerto Rico at USD29,400 per 30-day supply.

For those who qualify, Rigel says that it offers patient assistance programs for patients prescribed VEPPANU by their doctor. RIGEL ONECARE, the company's comprehensive patient support centre, can help patients and physicians as they navigate insurance coverage requirements and provide financial assistance when needed and if eligible, along with other support programs.

In May 2026, Rigel announced that it entered into an exclusive, global license agreement with Arvinas, Inc. and Pfizer Inc. to develop, manufacture and commercialize VEPPANU.